Table 1

Allele frequencies in RCC cases and controlsa

EnzymeAllele or genotypeFrequency (%)
ControlsReferencesbCases
CYP1A1cCYP1A1*1 (wt)86.289.381.9
CYP1A1*2A 5.55.08.2
CYP1A1*2B 2.82.73.5
CYP1A1*3 0.00.00.0
CYP1A1*4 5.53.06.4
CYP2D6CYP2D6 (wt)d73.072.571.2
CYP2D6*3 1.41.81.2
CYP2D6*4 19.720.418.9
CYP2D6*5 2.62.54.6
CYP2D6*6 1.911.2
CYP2D6*8 0.0<0.10.0
CYP2D6*10 1.41.72.9
CYP2D6*12 0.0<0.10.0
CYP2D6*14 0.00.00.0
NQO1NQO1*1 (wt)80.581.376.3
NQO1*2 19.518.723.7
GSTM1 GSTM1*0/*0 55.553.351.4
GSTM1*A/*A and GSTM1*A/*022.730.329.5
GSTM1*B/*B and GSTM1*B/*017.513.013.9
GSTM1*A/*B 4.33.45.2
GSTT1GSTT1 wt/wt and GSTT1 wt/*081.080.585.6
GSTT1*0/*0 19.019.514.4
GSTP1GSTP1*A (wt)69.070.365.3
GSTP1*B 31.029.734.7
GSTP1*C 0.0e0.0
NAT2NAT2*4 (wt)25.324.323.3
NAT2*5 45.346.548.1
NAT2*6 28.027.326.4
NAT2*7 1.21.81.9
NAT2*14 0.2<0.10.3
  • a The frequencies obtained are for: 210–211 controls and 171–173 RCC cases for CYP1A1, CYP2D6, NQO1, GSTM1, and GSTT1; 211 controls and 159 RCC patients for NAT2; and 189 controls and 160 RCC patients for GSTP1.

  • b Reference data are taken from studies with European Caucasians, restricted to those with similar distributions of age and sex, as the control subjects: 880 individuals (42) for CYP1A1; 784 individuals (33 , 43) for CYP2D6; 235 individuals (20 , 44) for NQO1; 950 individuals (18 , 45) for GSTM1; 867 individuals (18 , 45) for GSTT1; 180 individuals (46) for GSTP1; and 1128 individuals (18 , 47 48 49) for NAT2.

  • c Nomenclature of alleles is as described by Cascorbi et al. (42) .

  • d CYP2D6 (wt) represents the alleles associated with normal or ultrarapid CYP2D6 activity; the CYP2D6*10 allele has also been excluded from the PM alleles (33 , 50) .

  • e No data have been reported with regards to GSTP1*C allele frequency in Caucasians.